CAS 725735-28-4
:Intetumumab
Description:
Intetumumab, identified by the CAS number 725735-28-4, is a monoclonal antibody that primarily targets the immune checkpoint protein known as CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). This protein plays a crucial role in downregulating immune responses, and by inhibiting its function, Intetumumab aims to enhance the immune system's ability to recognize and attack cancer cells. The substance is part of a broader class of immunotherapeutic agents that are being explored for their potential in treating various malignancies, particularly in oncology. Intetumumab is characterized by its specificity for CTLA-4, which is expressed on activated T cells, and its mechanism of action involves blocking the interaction between CTLA-4 and its ligands, thereby promoting T cell activation and proliferation. As a therapeutic agent, it is typically administered via injection and is subject to rigorous clinical evaluation to assess its efficacy and safety profile in cancer treatment.
Formula:Unspecified
Synonyms:- CNTO 95
- Intetumumab
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Intetumumab
CAS:Intetumumab (CNTO 95) is a fully humanized anti-α(v)-integrin monoclonal antibody that is a radiosensitizer for xenograft tumor-bearing mice.Purity:97.6% (SDS-PAGE); 97.1% (SEC-HPLC) - 97.6% (SDS-PAGE); 97.1% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.56 kDa (Predicted)
